How to Join a Psilocybin Clinical Trial in 2026
For most Americans outside of Oregon and Colorado, clinical trials are the most accessible path to legal, medically supervised psilocybin therapy. Trials are free, conducted by qualified researchers, and provide rigorous screening and support. Here's how to find and access them.
Why Consider a Clinical Trial
It's free: Participants typically receive psilocybin sessions, preparation therapy, integration therapy, and all medical monitoring at no cost.
Expert oversight: Principal investigators and research staff are among the most experienced people in the field. The safety protocols are more rigorous than most private settings.
Scientific contribution: Participation contributes to the evidence base that drives policy change and eventual FDA approval.
Access before approval: In states without legal service centers, trials may be the only legal option.
How to Find Open Trials
ClinicalTrials.gov is the primary database. Search for "psilocybin" filtered by "recruiting" status and your country/state. As of 2026, dozens of active psilocybin trials are open in the US across many research centers.
Major research centers currently running psilocybin trials:
- Johns Hopkins Center for Psychedelic and Consciousness Research (Baltimore, MD)
- NYU Langone Health Psychedelic Research Program (New York, NY)
- UCSF Neuroscape (San Francisco, CA)
- University of Wisconsin-Madison
- Mass General Hospital / Harvard (Boston, MA)
- Yale School of Medicine (New Haven, CT)
- UC Boulder (Boulder, CO)
- Sheppard Pratt (Baltimore, MD)
Conditions Currently Being Studied
Active psilocybin trials in 2026 cover:
- Treatment-resistant depression (MDD)
- Major depressive disorder
- Alcohol use disorder
- Tobacco / nicotine dependence
- OCD (obsessive-compulsive disorder)
- Anorexia nervosa
- End-of-life anxiety (life-threatening illness)
- PTSD (veteran populations)
- Eating disorders
- Generalized anxiety disorder
Eligibility and Screening
Each trial has its own inclusion and exclusion criteria. Common exclusions across most psilocybin trials:
Typically excluded:
- Personal or first-degree family history of psychosis, schizophrenia, or bipolar I
- Current lithium use (risk of serotonin syndrome / seizures)
- Severe cardiovascular disease
- Current severe suicidality requiring hospitalization
- Active substance use disorder (for trials targeting other conditions)
- Pregnancy or breastfeeding
- Certain medications (MAOIs, antipsychotics, some antidepressants)
You'll be asked about your psychiatric and medical history in detail. Be honest — exclusion criteria exist for safety reasons, not gatekeeping.
What to Expect After Applying
- Initial screening call: 30–60 minutes with a research coordinator to review eligibility
- In-person screening: Medical and psychiatric evaluation, often including urine drug screen, EKG, blood work
- Preparation sessions: Several therapy sessions with research staff before psilocybin administration
- Psilocybin session(s): 1–2 supervised sessions in a clinical setting
- Integration sessions: Follow-up therapy sessions after the psilocybin experience
- Follow-up assessments: Psychological assessments at 1 month, 3 months, 6 months, sometimes 12 months
The entire process from application to completion typically takes 3–6 months.
Practical Considerations
Travel: Many trials require you to be in-person near the research site for the screening, sessions, and follow-up. Some researchers will conduct integration sessions by telehealth. Consider whether you can commit to travel.
Time commitment: Between screening, preparation, sessions, and follow-up visits, expect to allocate 15–25 hours spread over 3–6 months.
Randomization: Some trials are randomized and placebo-controlled — you may be assigned to the control group (placebo or low dose). Most reputable trials offer crossover or open-label extension to ensure all participants eventually receive active treatment.
Resources
- ClinicalTrials.gov: Search "psilocybin" + recruiting + your region
- PsychedelicSupport.com: Lists trials with patient-friendly descriptions
- Johns Hopkins CPCR: hopkinspsychedelic.org
- NYU Psychedelic Research: nyulangone.org/research/psychedelic-research